FDA Grants Approval for L-Glutamine ANDA219722 by Annora Pharma
The FDA has granted approval for Annora Pharma's ANDA219722 for L-Glutamine.
Published: July 20, 2026
Updated: July 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Rare Diseases / Urea Cycle Disorders
Company: Annora Pharma
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Annora Pharma
Asset
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
The FDA's approval of Annora Pharma's L-Glutamine presents a significant opportunity in the rare disease market, particularly for urea cycle disorders. This development necessitates close monitoring of competitive dynamics and market strategies as it may influence market share and positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry strategies and sales performance of L-Glutamine post-approval.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.